Why Senores Pharma Share Price is Rising

The Indian stock market has been quite volatile lately.

Investors have been on edge due to global uncertainties, rising interest rates, and sectoral weaknesses. Even strong companies have faced selling pressure. The broader indices have struggled to maintain momentum, with frequent ups and downs.

However, amid this choppy market, one stock has stood strong-Senores Pharma.

The pharmaceutical company has defied the broader market trend. Investors have shown confidence in the stock despite the ongoing market turbulence. Its steady performance has made it a standout player in an otherwise shaky environment.

Since its listing, Senores Pharma has rallied 13.1%. In 2025 alone, the stock is up 10.3%, even as broader markets and strong companies faced a downturn.

Let's take a closer look at what's fueling Senores Pharma share price rally.

#1 Expanding Global Presence

Senores Pharma is gradually increasing its stake in Havix Group Inc., which operates as Aavis Pharmaceuticals.

With this acquisition, Senora has strengthened its control over the US-based pharmaceutical company. The move aligns with its strategy to expand in the international market and enhance its product portfolio.

Havix has shown steady financial growth in recent years. Its revenue rose from US$ 7.3 million (m) in 2022 to US$ 8.8 m in 2023, reaching US$ 14.4 m in the financial year ending March 2024.

The company develops and supplies a range of finished formulations, making it a valuable asset for Senora's long-term plans.

Investors have responded positively to this development. The stock has gained momentum as the market views this strategic move as a step toward future growth and profitability.

#2 Expanding Portfolio

Senores Pharma has strengthened its presence in the US market by acquiring an Abbreviated New Drug Application (ANDA) for Roflumilast tablets.

The drug is used to treat severe chronic obstructive pulmonary disease (COPD) linked to chronic bronchitis.

The US market for Roflumilast is valued at approximately US$ 32 m as of June 2024, according to IQVIA data. By adding this drug to its portfolio, Senora aims to enhance its respiratory product offerings and expand its revenue stream.

Investors view it as a step toward growth and profitability. As a result, Senores Pharma share price has gained momentum.

#3 New Facility

Senores Pharma has commenced operations at its newly built active pharmaceutical ingredient (API) manufacturing facility in Mehsana, Gujarat.

The plant spans approximately 230,000 sq. ft. and has an annual production capacity of around 100 metric tons. This is the company's second API facility, significantly boosting its production capabilities.

The new plant will strengthen Senora's position in regulated markets, particularly in contract development and manufacturing (CDMO) and contract manufacturing (CMO) businesses.

Senores Pharma currently holds 24 approved ANDAs and 21 commercial CDMO/CMO products in the US. Additionally, it supplies generic drugs to over 40 countries and operates multiple manufacturing facilities in India and the US.

The market has responded positively to this expansion. Investors view the facility as a key growth driver for the company's long-term success.

What Next?

Senores Pharma has laid a strong foundation for future growth. The company is expanding its presence in regulated markets, particularly the US, which remains its biggest revenue driver.

It has a robust pipeline of 51 products, including 28 with Competitive Generic Therapy (CGT) potential. Five new product launches are expected in Q4 FY25, with more in the pipeline for the coming quarters.

The contract development and manufacturing (CDMO) and contract manufacturing (CMO) segments are also key growth areas. Senora has 21 commercial products in this segment and 69 in the pipeline.

Its partnerships with large pharmaceutical companies provide steady revenue streams and expansion opportunities.

The company is also strengthening its API and critical care injectables businesses. With a new API facility in Mehsana and increasing global demand, these segments are expected to contribute more to overall revenue.

Emerging markets are also a focus, with Senora expanding its reach across Latin America, Africa, and Asia.

The company's growth strategy is backed by research and development. It continues to invest in differentiated and complex pharmaceutical products.

Investors should also evaluate corporate governance as a key factor when conducting due diligence before making investment decisions.

How Senores Pharma Share Price has Performed Recently

In the past five days, Senores Pharma share price has rallied 13.3%. In the last month, it is up 22.9%.

Since its listing, the share price is up 13.1%.

The stock touched its 52-week high of Rs 644.4 on 6 February 2025 and a 52-week low of Rs 440 on 13 January 2025.

About Senores Pharma

Senores Pharma is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

Senora is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries.

For more details, checkout the Senores Pharma company fact sheet and its quarterly results.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...